Study to Assess the Effect of Osimertinib (TAGRISSO ™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Condition:   Non Small Cell Lung Cancer Interventions:   Drug: Fexofenadine tablet dosing;   Drug: Osimertininb tablet dosing Sponsors:   AstraZeneca;   Quintiles, Inc. Not yet recruiting - verified September 2016

Source: ClinicalTrials.gov - August 23, 2016 Category: Research Source Type: clinical trials